724 related articles for article (PubMed ID: 31860674)
1. Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition.
Kettunen J; Holmes MV; Allara E; Anufrieva O; Ohukainen P; Oliver-Williams C; Wang Q; Tillin T; Hughes AD; Kähönen M; Lehtimäki T; Viikari J; Raitakari OT; Salomaa V; Järvelin MR; Perola M; Davey Smith G; Chaturvedi N; Danesh J; Di Angelantonio E; Butterworth AS; Ala-Korpela M
PLoS Biol; 2019 Dec; 17(12):e3000572. PubMed ID: 31860674
[TBL] [Abstract][Full Text] [Related]
2. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
Ference BA; Kastelein JJP; Ginsberg HN; Chapman MJ; Nicholls SJ; Ray KK; Packard CJ; Laufs U; Brook RD; Oliver-Williams C; Butterworth AS; Danesh J; Smith GD; Catapano AL; Sabatine MS
JAMA; 2017 Sep; 318(10):947-956. PubMed ID: 28846118
[TBL] [Abstract][Full Text] [Related]
3. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
[TBL] [Abstract][Full Text] [Related]
4. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study.
Ordovas JM; Cupples LA; Corella D; Otvos JD; Osgood D; Martinez A; Lahoz C; Coltell O; Wilson PW; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1323-9. PubMed ID: 10807749
[TBL] [Abstract][Full Text] [Related]
5. LDL size distribution in relation to insulin sensitivity and lipoprotein pattern in young and healthy subjects.
Ambrosch A; Mühlen I; Kopf D; Augustin W; Dierkes J; König W; Luley C; Lehnert H
Diabetes Care; 1998 Dec; 21(12):2077-84. PubMed ID: 9839097
[TBL] [Abstract][Full Text] [Related]
6. Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia.
Poliakova T; Wellington CL
Mol Neurodegener; 2023 Nov; 18(1):86. PubMed ID: 37974180
[TBL] [Abstract][Full Text] [Related]
7. Relationship of genetic variation in genes encoding apolipoprotein A-IV, scavenger receptor BI, HMG-CoA reductase, CETP and apolipoprotein E with cholesterol metabolism and the response to plant stanol ester consumption.
Plat J; Mensink RP
Eur J Clin Invest; 2002 Apr; 32(4):242-50. PubMed ID: 11952809
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
9. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
[TBL] [Abstract][Full Text] [Related]
10. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
[TBL] [Abstract][Full Text] [Related]
11. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; McCrary Sisk C; Dansky H; Mitchel Y; Barter P;
J Clin Lipidol; 2015; 9(1):65-71. PubMed ID: 25670362
[TBL] [Abstract][Full Text] [Related]
12. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
13. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein Characteristics and Incident Coronary Heart Disease: Prospective Cohort of Nearly 90 000 Individuals in UK Biobank.
Jin D; Trichia E; Islam N; Bešević J; Lewington S; Lacey B
J Am Heart Assoc; 2023 Oct; 12(20):e029552. PubMed ID: 37815053
[TBL] [Abstract][Full Text] [Related]
15. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
[TBL] [Abstract][Full Text] [Related]
16. Association between lipids, lipoproteins composition of HDL particles and triglyceride-rich lipoproteins, and LCAT and CETP activity in post-renal transplant patients.
Kimak E; Bylina J; Solski J; Hałabiś M; Baranowicz-Gąszczyk I; Książek A
Cell Biochem Biophys; 2013 Nov; 67(2):695-702. PubMed ID: 23479335
[TBL] [Abstract][Full Text] [Related]
17. Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin.
Contacos C; Barter PJ; Vrga L; Sullivan DR
Atherosclerosis; 1998 Nov; 141(1):87-98. PubMed ID: 9863541
[TBL] [Abstract][Full Text] [Related]
18. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
Ference BA; Kastelein JJP; Ray KK; Ginsberg HN; Chapman MJ; Packard CJ; Laufs U; Oliver-Williams C; Wood AM; Butterworth AS; Di Angelantonio E; Danesh J; Nicholls SJ; Bhatt DL; Sabatine MS; Catapano AL
JAMA; 2019 Jan; 321(4):364-373. PubMed ID: 30694319
[TBL] [Abstract][Full Text] [Related]
19. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
[TBL] [Abstract][Full Text] [Related]
20. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
